HKSE - Delayed Quote HKD

Jacobson Pharma Corporation Limited (2633.HK)

Compare
1.020
0.000
(0.00%)
At close: 4:08:28 PM GMT+8
Currency in HKD All numbers in thousands
Download
Breakdown
TTM
3/31/2024
3/31/2023
3/31/2022
3/31/2021
Total Revenue
1,467,798.000
1,467,798.000
1,267,598.000
1,595,543.000
1,445,915.000
Cost of Revenue
847,323.000
847,323.000
728,680.000
975,021.000
884,832.000
Gross Profit
620,475.000
620,475.000
538,918.000
620,522.000
561,083.000
Operating Expense
332,287.000
332,287.000
268,829.000
400,133.000
326,520.000
Operating Income
288,188.000
288,188.000
270,089.000
220,389.000
234,563.000
Net Non Operating Interest Income Expense
-54,702.000
-54,702.000
-43,537.000
-23,798.000
-28,056.000
Pretax Income
254,583.000
254,583.000
250,345.000
231,433.000
220,569.000
Tax Provision
44,414.000
44,414.000
42,976.000
43,728.000
34,264.000
Net Income Common Stockholders
266,968.000
266,968.000
251,044.000
177,666.000
173,713.000
Diluted NI Available to Com Stockholders
266,968.000
266,968.000
251,044.000
177,666.000
173,713.000
Basic EPS
0.14
--
0.13
0.09
0.09
Diluted EPS
0.14
--
0.13
0.09
0.09
Basic Average Shares
1,911,361.000
--
1,920,196.000
1,915,677.000
1,916,167.000
Diluted Average Shares
1,911,361.000
--
1,920,196.000
1,915,677.000
1,916,167.000
Total Operating Income as Reported
333,126.000
333,126.000
313,384.000
260,888.000
256,240.000
Rent Expense Supplemental
--
6,708.000
499.000
812.000
--
Total Expenses
1,179,610.000
1,179,610.000
997,509.000
1,375,154.000
1,211,352.000
Net Income from Continuing & Discontinued Operation
266,968.000
266,968.000
251,044.000
177,666.000
173,713.000
Normalized Income
185,062.899
185,062.899
177,867.090
174,581.556
165,393.514
Interest Income
24,006.000
24,006.000
17,875.000
1,889.000
2,088.000
Interest Expense
78,708.000
78,708.000
61,412.000
25,687.000
30,144.000
Net Interest Income
-54,702.000
-54,702.000
-43,537.000
-23,798.000
-28,056.000
EBIT
333,291.000
333,291.000
311,757.000
257,120.000
250,713.000
EBITDA
333,291.000
489,813.000
496,217.000
449,717.000
442,414.000
Reconciled Cost of Revenue
847,323.000
847,323.000
728,680.000
975,021.000
884,832.000
Reconciled Depreciation
--
156,522.000
184,460.000
192,597.000
191,701.000
Net Income from Continuing Operation Net Minority Interest
186,359.000
186,359.000
175,204.000
177,666.000
173,710.000
Total Unusual Items Excluding Goodwill
1,570.000
1,570.000
-3,215.000
3,803.000
9,846.000
Total Unusual Items
1,570.000
1,570.000
-3,215.000
3,803.000
9,846.000
Normalized EBITDA
331,721.000
488,243.000
499,432.000
445,914.000
432,568.000
Tax Rate for Calcs
0.000
0.000
0.000
0.000
0.000
Tax Effect of Unusual Items
273.899
273.899
-551.910
718.556
1,529.514
3/31/2021 - 9/21/2016

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

2161.HK JBM (Healthcare) Limited
1.690
-1.17%
 
1513.HK LIVZON PHARMA
25.600
-0.58%
 
0719.HK SHANDONG XINHUA
5.540
-1.25%
 
0570.HK TRAD CHI MED
2.050
-0.49%
 
1681.HK CONSUN PHARMA
7.500
-0.53%
 
6483.TWO Original BioMedicals Co., Ltd.
10.75
-2.27%
 
4172.TWO InnoPharmax Inc.
16.20
-1.22%
 
4120.TWO Orient EuroPharma Co., Ltd.
47.00
-0.63%
 
3054.TW LIWANLI Innovation Co., Ltd.
20.60
-1.90%
 
6576.TWO Foresee Pharmaceuticals Co., Ltd.
76.30
0.00%